Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 7;10:13311. doi: 10.1038/s41598-020-69327-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Clinical outcomes of Coxevac vaccination and Cb challenge in tgHLA-DR3 mice. (A) Treatment groups and numbers of mice for the tgHLA-DR3 study (B) Experimental schedule. Mice were injected subcutaneously with saline or 10 µg Coxevac on day 0. After 42 days mice were challenged intranasally with live Cb. Whole blood was collected for CyTOF analysis on Day 10, 35, 44 and 51. Sera were collected for serology on Day 10, 24 and 35. (C) Antibody production against Cb was evaluated at Day 10, 24, and 35 post-vaccination by ELISA (D) Spleen-to-body-weight ratio and (E) spleen bacterial burden (genome equivalents (GE) determined by qPCR) were assessed for each of the experimental groups. Significant differences between experimental groups in panels (C–E) were assessed by one-way ANOVA with the Tukey post-hoc multiple comparison correction (****p = 0.0001, ***p < 0.0003, *p < 0.01). (F) Histopathological scores from lung, liver, spleen, and heart. Kruskal–Wallis test was used to compare between groups (^###p = 0.0003, ^##p = 0.005).